I agree. This reads well. There are so many things going on, and revenue seems to be gaining traction. Once it achieves CF+, will support their drug development program (much like CUV). With ~30ml in cash, and a current revenue run rate of ~16ml, at a 47ml EV, puts it on ~3 times revenue. This looks like good value for a unique offering company with lots of levers to the upside.
- Forums
- ASX - By Stock
- Ann: Q3 FY24 Quarterly Investor Presentation
I agree. This reads well. There are so many things going on, and...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MAP (ASX) to my watchlist
|
|||||
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.13M |
Open | High | Low | Value | Volume |
17.0¢ | 17.0¢ | 17.0¢ | $70.70K | 415.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 26337 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 0.170 |
2 | 19180 | 0.165 |
2 | 9785 | 0.160 |
1 | 2430 | 0.155 |
2 | 34980 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 26337 | 1 |
0.185 | 6000 | 1 |
0.195 | 32660 | 1 |
0.200 | 71786 | 4 |
0.205 | 25000 | 1 |
Last trade - 10.59am 05/07/2024 (20 minute delay) ? |
Featured News
MAP (ASX) Chart |